CORAL GABLES, FL, September 10, 2013
-- Catalyst Pharmaceutical Partners, Inc. (Nasdaq
:
CPRX) today reported that it has closed its prev
iously announced offering of 8.8 million shares
of its common stock in a registered direct
public offering. The offering price was $1.72 per
share, resulting in gross proceeds of approximate
ly $15.1 million. Roth Capital Partners acted as
the exclusive placement agent for the offeri
ng and Aegis Capital Corp., Maxim Group LLC and
H.C. Wainwright & Co. acted as financial
advisers with respect to the offering.

Patrick J. McEnany, Catalyst's Chairman and CE
O, stated: “We are pleased to have completed
this financing, which we believe, along with the
proceeds from recent warrant exercises, gives us
the capital necessary to fund de
velopment of Firdapse™ and allo
ws us to begin new clinical
studies for CPP-115." Mr. McEna
ny continued: "We are also exci
ted that several high quality
fundamental life science investor
s, including New Leaf Venture Pa
rtners, particip
ated in our
offering."

Dr. Mark G. Charest of New Leaf
Venture Partners, st
ated: “New Leaf is
pleased to support the
development of Firdapse™ under the recently gr
anted ‘Breakthrough Therapy Designation.’ We
are excited about the po
tential for Firdapse™.”

The shares were offered pursuant to a shelf re
gistration statement on Form S-3 (File No. 333-
170945) filed pursuant to the Secu
rities Act of 1933, as amended,
which was previously filed
with, and declared effective by, the Securities
and Exchange Commission
(SEC). A prospectus
supplement relating to the offering has been file
d with the SEC and is
available on the SEC's
website at http://www.sec.gov.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer
to buy, nor shall there be any sale of these securi
ties in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful
prior to registration or
qualification under the
securities laws of any su
ch state or jurisdiction.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a
specialty pharmaceutical company focused on the
development and commercialization of novel
prescription drugs targ
eting rare (orphan)
neuromuscular and neurological diseases, in
cluding Lambert-Eaton Myasthenic Syndrome
(LEMS), infantile spasms, and Tourette Syndrome.
Catalyst's lead candidate, Firdapse™ for the
treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III
trial and recently received
"Breakthrough Therapy Designation"
from the U.S. Food & Drug
Administration (FDA). Catalyst is
also developing a potentially sa
fer and more potent vigabatrin
analog (designated CPP-115)
to treat infantile spasms, and epile
psy, as well as other neurological
conditions associated with reduced GABAergic si
gnaling, like post-traumatic stress disorder and
Tourette Syndrome.

Forward-Looking Statements

This press release contains fo
rward-looking statements. Forwar
d-looking statements involve
known and unknown risks and uncertainties, which may
cause Catalyst's actua
l results in future
periods to differ materially from forecasted resu
lts. A number of factors, including the timing of
completion of Catalyst's currently ongoing Phase
III trial of Firdapse™, whether the Phase III
trial will be successful, whether
the receipt of breakthrough th
erapy designation for Firdapse™
will expedite the development and review of Firdapse™ by the FDA or the likelihood that the
product will be found to be safe and effective, wh
ether the proceeds of this offering, along with
the proceeds of recent warrant exercises, will be sufficient to fund the development of
Firdapse™ and to begin new cl
inical studies for CPP-115, whet
her an NDA for Firdapse™ will
ever be accepted for filing by the FDA, the
timing of any such NDA filing or acceptance,
whether, even if approved, Firdapse™ will
be the only approved treatment option for LEMS
patients, whether any of Catalyst's product candidates will ever be approved for
commercialization or successfully commercializ
ed, and those other f
actors described in
Catalyst's Annual Report on Form 10-K for the fis
cal year 2012 and other filings with the U.S.
Securities and Exchange Commis
sion (SEC), could adversely a
ffect Catalyst. Copies of
Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website
or may be obtained upon request
from Catalyst. Catalyst does not undertake any obligation to
update the information contained herein,
which speaks only as of this date.